• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Abdominal radiology. >Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT
【24h】

Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT

机译：使用双能CT进行化疗后胰腺癌的碘摄取评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic cancer remains a major health problem, and only less than 20% of patients have resectable disease at the time of initial diagnosis. Systemic chemotherapy is often used in the patients with borderline resectable, locally advanced unresectable disease and metastatic disease. CT is often used to assess for therapeutic response; however, conventional imaging including CT may not correctly reflect treatment response after chemotherapy. Dual-energy (DE) CT can acquire datasets at two different photon spectra in a single CT acquisition, and permits separating materials and extract iodine by applying a material decomposition algorithm. Quantitative iodine mapping may have an added value over conventional CT imaging for monitoring the treatment effects in patients with pancreatic cancer and potentially serve as a unique biomarker for treatment response. In this pictorial essay, we will review the technique for iodine quantification of pancreatic cancer by DECT and discuss our observations of iodine quantification at baseline and after systemic chemotherapy with conventional cytotoxic agents, and illustrate example cases.
机译：胰腺癌仍然是一个重大的健康问题，只有不到20％的患者在初步诊断时具有可重症的疾病。系统化疗通常用于临界可重型，局部晚期不可切除的疾病和转移性疾病的患者。 CT通常用于评估治疗反应;然而，包括CT的常规成像可能在化疗后可能无法正确反映治疗响应。双能量（DE）CT可以在单个CT采集中获取两种不同光子谱的数据集，并通过应用材料分解算法允许分离材料并提取碘。定量碘映射可具有常规CT成像的附加值，用于监测胰腺癌患者的治疗效果，并且可能用作独特的生物标志物进行治疗反应。在本文的文章中，我们将通过DECT审查碘定量胰腺癌的技术，并探讨了与常规细胞毒性剂的基线和全身化疗后碘定量的观察结果，并说明了实施例案例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号